Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fulzerasib + ivonescimab
- Development stage
- Unknown
- Lead developer
- GenFleet Therapeutics
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Fulzerasib + ivonescimab is an investigational combination therapy for advanced or metastatic non-small cell lung cancer (NSCLC), specifically targeting patients with KRAS G12C mutation. Fulzerasib is a covalent inhibitor of the KRAS G12C protein, developed as a targeted therapy for tumors bearing this genetic alteration. Ivonescimab is a bispecific monoclonal antibody targeting both PD-1 and VEGF, combining immune checkpoint inhibition with anti-angiogenic therapy. The combination aims to simultaneously block cancer cell signaling and modulate the tumor microenvironment by suppressing immune evasion and angiogenesis. This combination is being evaluated in early phase clinical trials as first-line therapy for NSCLC with KRAS G12C mutation.
- Brand names
- Dupert + Yidafan
- Other names
- fulzerasib + ivonescimabIBI351 + ivonescimabGFH925 + ivonescimab
02
Targets
VEGFA (Vascular endothelial growth factor A)KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on fulzerasib + ivonescimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fulzerasib + ivonescimab.